RecruitingPhase IInterventional

Deferred registration: Phase I Trial: MAC code 'MAC215'

MAC215 is an early-stage clinical study (Phase 1) designed for adults aged between 50 and 85 years old. In the UK, researchers can apply to delay publishing the full details of a study to protect sensitive scientific or commercial information. The Health Research Authority (HRA) has approved this temporary delay. Because of this, specific information about the condition being treated and the study medicine is not yet publicly available. However, Phase 1 trials generally test the safety of a new treatment and check for potential side effects under close medical supervision. Full details must be added to the public register within 30 months of the study finishing. If a doctor suggests this trial to you, they will provide a full information sheet before you decide whether to take part.

At a glance

Status

Recruiting

Phase

Phase I

Sponsor

Neurocrine Biosciences (United States)

Enrolment target

Start

22 May 2026

Estimated completion

15 Feb 2027

The Health Research Authority has approved a deferral. Full details will be added to the trial record on or before the deferral expiry date.

What is this study about?

This clinical trial, identified by the code MAC215, is an early-stage study known as a Phase 1 trial. Phase 1 is typically the first time a new medicine or therapy is tested in humans. The main goal of these studies is to check that a treatment is safe to use, find the right dose, and see how the human body reacts to it.

Currently, the full scientific details of MAC215 are not available to the public. In the UK, the Health Research Authority (HRA) can grant a 'deferred registration'. This allows study sponsors to keep certain details confidential for a limited time, often to protect early discoveries or patents while initial tests are completed.

Even though the public record is limited, the trial must still follow strict UK safety regulations and receive ethical approval. A research ethics committee checks the study to make sure participants are treated fairly and kept as safe as possible. Once the trial ends, the researchers are legally required to publish the results so the wider medical community can learn from them.

Key takeaways

MAC215 is an early-stage (Phase 1) clinical trial focusing on safety.
The trial is open to adults aged between 50 and 85 years old.
Detailed study information is temporarily delayed with UK ethics approval.
Full details will be published on public registers after the study finishes.
Taking part is completely voluntary, and you can withdraw at any time.

Who may be eligible?

To be considered for this study, you must be between 50 and 85 years old. Both men and women within this age group may be able to take part.

Because the full trial details are temporarily withheld, the specific medical conditions, health history, or background needed to join have not yet been published.

If you are approached about this study by your doctor or a research centre, they will review your full medical records and explain whether you meet the exact health requirements.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

I am aged between 50 and 85 years old.
I am interested in taking part in early medical research.
I am able to travel to a UK research clinic for health check-ups.
I am happy to discuss my full medical history with a study doctor.

Answer every question to see your result.

What does participation involve?

Because this study's plan is currently private, exact details about appointment schedules and medications are not publicly available. In general, Phase 1 studies involve close medical monitoring. This usually includes regular visits to a hospital or specialised research clinic, physical health exams, and routine tests such as blood tests, blood pressure checks, and heart traces (ECGs). You may receive the trial treatment as a tablet, an injection, or an infusion. The study team will explain the total number of visits, how long each appointment takes, and any follow-up care before you agree to take part.

Potential risks and benefits

Phase 1 studies are designed to test safety rather than cure an illness, so taking part may not directly improve your health. However, you will receive close, careful medical attention from the research team throughout the study. Because the treatment is in its early stages, there is always a risk of unexpected side effects or mild discomfort from clinic tests. Taking part is completely voluntary. You are free to stop and leave the trial at any time, and doing so will never affect the standard NHS care you receive.

Locations (8)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

MAC Clinical Research Manchester
City only
Manchester, England
MAC Clinical Research Teesside
City only
Stockton-on-Tees, England
MAC Clinical Research Cannock
City only
South Staffordshire, England
MAC Clinical Research Blackpool
City only
Blackpool, England
MAC Clinical Research Barnsley
City only
Barnsley, England
MAC Clinical Research Leeds
Unverified
Leeds, England
MAC Clinical Research Liverpool
Unverified
Liverpool, England
MAC Clinical Research Glasgow
Unverified
Glasgow, England

Common questions

Why are the details of this study kept private?

The UK Health Research Authority has allowed the researchers to delay publishing details to protect sensitive scientific discoveries. Full details will be shared publicly after the study ends.

What does a Phase 1 trial mean?

Phase 1 is the earliest stage of human testing. It focuses mainly on finding out if a new treatment is safe and what side effects it might cause.

Is the trial safe if the details are not public?

Yes, the study still has to follow strict UK laws and pass rigorous reviews by an independent ethics committee to ensure participant safety.

Will taking part cure my condition?

Phase 1 studies are designed to check treatment safety rather than cure an illness, so personal health benefits cannot be guaranteed.

Can I leave the study if I change my mind?

Yes. Joining a clinical trial is always your choice, and you can withdraw at any point without giving a reason.

How to find out more

Adam Uchimoto

auchimoto@neurocrine.com - Official trial record

Always speak to your GP or specialist before deciding to take part in a study.